Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
06/2005
06/23/2005DE10356112A1 Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem in den Prostglandinstoffwechsel eingreifendem Wirkstoff A pharmaceutical composition comprising a beta 3-adrenoceptor agonist and an eingreifendem in the Prostglandinstoffwechsel agent
06/23/2005DE10352450A1 Composition, useful for prophylaxis and/or treatment of Alzheimer's disease, comprises sphingosine, sphingosine biosynthesis activator or sphingosine biodegradation inhibitor
06/23/2005CA2561746A1 Methods and compounds for modulating triglyceride and vldl secretion
06/23/2005CA2549574A1 The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist
06/23/2005CA2547570A1 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione for induction of fetal hemoglobin in individuals having anemia
06/23/2005CA2490218A1 Extracorporeal photopheresis in combination with anti-tnf treatment
06/22/2005EP1543848A1 High strength suture with absorbable core and suture anchor combination
06/22/2005EP1543325A2 Flea and tick octopamine receptor nucleic acid molecules, proteins and thereof
06/22/2005EP1543166A2 Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome
06/22/2005EP1543165A2 Assays for assembly of ebola virus nucleocapsids
06/22/2005EP1543119A2 Methods of inhibiting hiv-1 vpr activity and hiv-1 infectivity using atr or rad17 inhibitors
06/22/2005EP1543034A2 Treatment and prophylaxis with 4-1bb-binding agents
06/22/2005EP1543025A2 Human g protein-coupled receptor and modulators thereof for the treatment of ischemic heart disease and congestive heart failure
06/22/2005EP1543024A2 Cyclic amp phosphodiesterase 4d7 isoforms and methods of use
06/22/2005EP1543009A1 Pyrrolotriazine kinase inhibitors
06/22/2005EP1542999A1 1h-pyrazole and 1h-pyrrole-azabicyclic compounds with alfa-7 nachr activity
06/22/2005EP1542972A2 Cyclooxygenase- 2 selective inhibitors, compositions and methods of use
06/22/2005EP1542719A2 Methods and compositions for control of bone formation via modulation of sympathetic tone
06/22/2005EP1542714A1 Methods of increasing platelet and hematopoietic stem cell production
06/22/2005EP1542702A2 Methods and compositions for treatment of neurological disorder
06/22/2005EP1542698A2 Modulation of matrix metalloproteinase (mmp) activity with aldosterone blocker(s)
06/22/2005EP1542682A2 Novel inhibitors of ubiquitin isopeptidases
06/22/2005EP1542677A1 COMBINATIONS OF ATORVASTATIN AND a1, ADRENERGIC RECEPTOR ANTA GONISTS
06/22/2005EP1542671A1 Composition based on triethyl citrate for the treatment of bacterial infections of the skin
06/22/2005EP1542670A1 Composition containing arachidonic acid alone or in combination with docosahexaenoic acid for enhancing cognitive abilities
06/22/2005EP1542656A1 Antibiotic product, use and formulation thereof
06/22/2005EP1542528A1 A method of treatment and prophylaxis
06/22/2005EP1305057B1 Microparticulate biomaterial composition of hyaluronic acid for medical use
06/22/2005EP1272200B1 Divided dose therapies with vascular damaging activity
06/22/2005EP1196188B1 Vgf selective monoclonal antibodies and their use for treating vgf-related disorders
06/22/2005EP1140273B1 Device for locally delivering a drug in a body cavity
06/22/2005EP1131039B1 Use of a substance binding with the peripheral benzodiazepin receptor for treating skin stress
06/22/2005EP1073465B1 T cell inhibitory receptor compositions and uses thereof
06/22/2005EP1040111B1 Integrin receptor antagonists
06/22/2005EP1009411B1 Treatment of sleep apnea
06/22/2005EP0932416B1 Method and potentiated composition for treating migraine
06/22/2005CN1630730A Methods for detecting and treating the early onset of aging-related conditions
06/22/2005CN1630709A Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
06/22/2005CN1630708A Osteoclast-associated receptor
06/22/2005CN1630664A Caspase-8 binding protein, its preparation and use
06/22/2005CN1630645A 5-HT receptor ligands and uses thereof
06/22/2005CN1630641A Farnesyl protein transferase inhibitors as antitumor agents
06/22/2005CN1630638A Aryl ureas as kinase inhibitors
06/22/2005CN1630635A Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these
06/22/2005CN1630535A Inhibition of STAT-1
06/22/2005CN1630534A Methods and compositions for treating hyperproliferative conditions
06/22/2005CN1630532A Methods for prevention and treatment of gastrointestinal disorders
06/22/2005CN1630530A Polyalkylene polymer compounds and uses thereof
06/22/2005CN1630529A B-cell lymphoma specific antigen for use in diagnosis and treatment of B-cell malignancies
06/22/2005CN1630526A Systems and methods for treating patients with processed lipoaspirate cells
06/22/2005CN1630521A Oral compositions and methods for prevention, reduction and treatment of radiation injury
06/22/2005CN1630518A Methods of treating and preventing bone loss
06/22/2005CN1630516A Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents
06/22/2005CN1630514A Methods and compositions for control of bone formation via modulation of sympathetic tone
06/22/2005CN1630512A Pharmaceutical tablet
06/22/2005CN1630509A Compositions and methods for delivering antibacterial, antifungal and antiviral ointments to the oral, nasal or vaginal cavity
06/22/2005CN1630497A Drug delivery device
06/22/2005CN1628854A Sustained release medicine for artificially inducing sex reversal of grouper and its preparation method
06/22/2005CN1628853A Anti-cancer medicine composition
06/22/2005CN1628852A Anti solid tumor medicine composition
06/22/2005CN1628851A Anti-cancer medicine composition
06/22/2005CN1628850A Anti solid tumor medicine composition
06/22/2005CN1628849A Anti-cancer medicine composition
06/22/2005CN1628848A Multifunctional skin lotion for painless injection and trauma clearance
06/22/2005CN1628561A Combination for releasing lassitude and its preparation method and uses
06/22/2005CN1207288C Retroviral protease inhibiting compounds
06/22/2005CN1206984C Pellets having a core coated with an antifungal and a polymer
06/22/2005CN1206976C Compositions and method for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
06/22/2005CN1206963C Injection for eliminating wrinkles and scar and its prepn
06/22/2005CA2487107A1 Novel targets for obesity from skeletal muscle
06/22/2005CA2487098A1 Novel targets for obesity from fat tissue
06/21/2005US6909000 Inhibiting particularly the activity of hepatitis C virus NS3-NS4A protease; peptidomimetics having a bridged bicyclic moiety at the P2 position.
06/21/2005US6908943 Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of disease
06/21/2005US6908925 Administering to a candidate subject in need of such treatment, a thus-effective amount of at least one inhibitor of at least one calcium channel for loosening/slackening and/or relaxing cutaneous and/or subcutaneous human skin
06/21/2005US6908916 C-5 modified indazolylpyrrolotriazines
06/21/2005US6908907 Prevention and treatment of tumor growth, metastasis, and thromboembolic complications in cancer patients
06/21/2005US6908902 Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin
06/21/2005US6908741 Receptor for advanced glycated endproducts (RAGE); solid phase synthesis; immunoassay
06/21/2005US6908681 Silane copolymer coatings
06/21/2005US6908630 For therapy of inflammation, psoriasis
06/21/2005US6908623 Compositions and methods for enhancing receptor-mediated cellular internalization
06/21/2005US6908611 Combination therapies using vitamin B12 and interferon for treatment of viral, proliferative and inflammatory diseases
06/21/2005CA2382387C Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
06/21/2005CA2213339C Method of treating adenosine depletion
06/18/2005CA2490175A1 High strength suture with absorbable core
06/16/2005WO2005054460A1 Crystal of oxidized ldl-recognition domain of oxidized ldl receptor lox-1, stereostructure thereof and utilization of the same
06/16/2005WO2005054440A2 A biomimetic composition reinforced by a polyelectrolytic complex of hyaluronic acid and chitosan
06/16/2005WO2005054437A2 Compositions and methods for ex vivo preservation of blood vessels for vascular grafts using inhibitor of type i and/or type ii phosphodiesterases
06/16/2005WO2005054436A2 Compositions and methods for preservation of vascular grafts
06/16/2005WO2005054430A2 Hepatitis c virus inhibitors
06/16/2005WO2005054198A2 Therapeutics use of pyridinium compounds to modulate naadp activity
06/16/2005WO2005054181A1 Novel target protein of anticancer agent and novel anticancer agent (spnal) corresponding thereto
06/16/2005WO2005053795A2 Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
06/16/2005WO2005053744A1 TREATMENT OF RHEUMATOID ARTHRITIS WITH HYPOXIA-INDUCIBLE FACTOR 1α ANTAGONISTS
06/16/2005WO2005053742A1 Medicine containing antibody composition
06/16/2005WO2005053741A1 Medicine containing genetically modified antibody against chemokine receptor ccr4
06/16/2005WO2005053739A2 Combination therapy
06/16/2005WO2005053725A2 Cancer treatment
06/16/2005WO2005053719A2 Compositions for the treatment of diseases of the oral cavity and upper respiratory tract
06/16/2005WO2005053706A1 Use of a cyclopentenone prostaglandin for delaying for the onset and/or preventing the continuation of labour
1 ... 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 ... 1151